Longer mirdametinib treatment increased confirmed and deep responses as treatment-related adverse effects declined in neurofibromatosis type 1 tumors.
|Articles|March 9, 2011
- December 2010
- Volume 4
- Issue 12
Advisory Panel Discusses Expanded Indication for Avodart
Author(s)OBTN
The FDA has released briefing documents noting that the 5-alpha reductase inhibitor increases the risk of high-risk prostate cancer.
Advertisement
Prior to an upcoming advisory panel meeting to discuss whether GlaxoSmithKline’s Avodart (dutasteride) should receive an expanded indication as a chemopreventive for prostate cancer, the FDA has released briefing documents noting that the 5-alpha reductase inhibitor increases the risk of high-risk prostate cancer. Whatever the panel decides might affect a request from Merck to change the label on Proscar (finasteride) to reflect study findings that it reduces the rate of low-risk prostate cancer.
Articles in this issue
over 15 years ago
Medulloblastoma Subtypes Are Different Diseasesover 15 years ago
ASH 2010: Elotuzumab Highly Active in Patients With Advanced Myelomaover 15 years ago
FDA Requests Label Change for Generic DocetaxelAdvertisement
Related to this article
Age, geographic location, transportation barriers, and language and communication barriers may limit patient opportunities to participate in research.
Phase 2 Co-PSMA data showed higher lesion detection with 64Cu-SAR-bisPSMA vs 68Ga-PSMA-11 in biochemical recurrence after prostatectomy.
Retrospective data tie longer survival with niraparib maintenance to homologous recombination deficiency after complete primary debulking.
Experts weigh genomic testing, treatment intensification, and radioligand sequencing in advanced prostate cancer care.
Exploratory BEHOLD-1 data show responses to mocertatug rezetecan in platinum-resistant ovarian cancer across B7-H4 expression levels.
Updated BEHOLD-1 data show mocertatug rezetecan at its selected dose produced lasting responses in platinum-resistant ovarian cancer.
A dual antigen–targeted T-cell engager doublet produced durable PSA responses in late-line metastatic castration-resistant prostate cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Durvalumab Plus Enfortumab Vedotin for Cisplatin-Ineligible MIBC
2
Dr Gleave on Selecting Patients for Perioperative Therapy in High-Risk Prostate Cancer
3
Dr Calais on Individualizing PSMA-Targeted Therapy Sequencing in Prostate Cancer
4
CHMP Recommends Approval of Belzutifan Plus Lenvatinib for Advanced ccRCC After PD-(L)1 Inhibition
5